SCHEMBL23772148

SCHEMBL23772148

CC(C)(C)c1ccc(-c2c[nH]c(=O)[nH]c2=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.61
▸ LMNA P02545 2/20 0.48
▸ NOTUM Q6P988 1/20 0.41
▸ ATAD2 Q6PL18 1/20 0.41
▸ TNKS O95271 6/20 0.40
▸ TNKS2 Q9H2K2 5/20 0.40
▸ PARP1 P09874 2/20 0.40
▸ GNRHR P30968 2/20 0.39
▸ DGAT1 O75907 1/20 0.38
▸ BRD4 O60885 1/20 0.38
▸ CREBBP Q92793 1/20 0.38
▸ DPYD Q12882 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP19A1 P11511 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ THPO P40225 1/20 0.37
▸ MTOR P42345 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ HBB P68871 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28408957 0.83 ALDH1A1 (0.41) ALDH1A1LMNANOTUMTNKSTNKS2
SCHEMBL16652113 0.83 ALDH1A1 (0.61) ALDH1A1LMNANOTUMTNKSTNKS2
SCHEMBL16653102 0.80 ALDH1A1 (0.67) ALDH1A1LMNAATAD2BRD4DPYD
SCHEMBL29809206 0.77 ALDH1A1 (0.67) ALDH1A1LMNAATAD2DPYDGAA
SCHEMBL16652924 0.77 ALDH1A1 (0.67) ALDH1A1LMNAATAD2DPYDGAA
SCHEMBL16652457 0.76 ALDH1A1 (0.68) ALDH1A1LMNAGAASMN1; SMN2
SCHEMBL3485414 0.76 ALDH1A1 (1.00) ALDH1A1LMNAATAD2PARP1DPYD
SCHEMBL28408958 0.72 HTR1A (0.38) ALDH1A1LMNAATAD2GNRHRDPYD
SCHEMBL5801644 0.72 ALDH1A1 (0.64) ALDH1A1LMNAATAD2DPYDGAA
SCHEMBL16455963 0.71 BRD4 (0.43) ALDH1A1LMNANOTUMTNKSTNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11679093-B2 2-naphthimidamides, analogues thereof, and methods of treatment using same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2023-06-20 — — US disclosed
US-20210251942-A1 2-NAPHTHIMIDAMIDES, ANALOGUES THEREOF, AND METHODS OF TREATMENT USING SAME UNIV COLORADO REGENTS (US) 2021-08-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11679093-B2 2-naphthimidamides, analogues thereof, and methods of treatment using same TMPRSS2, TMPRSS4, TMPRSS15 ALDH1A1 2417/4885LMNA 428/4885NOTUM 1317/4885
US-20210251942-A1 2-NAPHTHIMIDAMIDES, ANALOGUES THEREOF, AND METHODS OF TREATMENT USING SAME TMPRSS2, TMPRSS4, TMPRSS15 ALDH1A1 2417/4885LMNA 428/4885NOTUM 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback